Lipoprotein(a)

The test is simple but underutilized. The speaker explains that unlike LDL cholesterol, which can be lowered with diet and exercise, Lp(a) is a 'fixed' risk factor that acts as a multiplier of overall cardiovascular risk. The thresholds used are roughly: <62 nmol/L (<30 mg/dL) low risk, 62–105 nmol/L (30–50 mg/dL) borderline elevated, >105 nmol/L (>50 mg/dL) elevated. Population data show a continuous relationship with risk, so even modest elevations matter. Because the test only needs to be done once, the cost is a one-time investment, which the speaker frames as $51 well spent to avoid missing a hidden driver of early heart disease. The low testing rate (1–2%) means millions are unaware they carry this risk, and the speaker urges viewers to proactively ask for the test or discuss it with their doctor.

This protocol is the centerpiece of the speaker's management strategy for high Lp(a). He reasons that because we cannot yet directly target Lp(a) levels with an approved drug, we must attack the variable that most powerfully modifies the risk equation: LDL cholesterol. The 40–50 mg/dL target is inspired by the new study's subgroup analysis, which essentially erased the excess risk of high Lp(a) when LDL was aggressively lowered. The speaker emphasizes that this is not a gentle recommendation—‘quite an aggressive target’—and typically requires medications. He notes that statins may slightly raise Lp(a) (an effect that made some clinicians hesitant historically), but the net cardiovascular outcome is positive, so that concern should not deter treatment. Ezetimibe is added for its complementary mechanism (intestinal cholesterol absorption inhibition) and excellent tolerability. Lifestyle changes remain foundational but are unlikely to achieve such low LDL alone in most people.

The speaker introduces aspirin as an additional risk-reduction tool specifically for the high-Lp(a) population. He notes that for most people, aspirin for primary prevention is no longer recommended, but the risk profile of high Lp(a) appears to change the calculation. The reasoning is that Lp(a) likely promotes both atherosclerosis and thrombosis (though the transcript only explicitly mentions inflammation and 6× more damage), so inhibiting platelet aggregation with aspirin could prevent events. The evidence base is still maturing—likely derived from post hoc analyses of older aspirin trials and observational studies—but the speaker is comfortable enough with the signal to incorporate it into his clinical decision-making as a consideration, not a blanket prescription.

The speaker frames total risk as a combined effect: 'Think of your total risk as a function of both your lipoprotein little A levels and all of the other risk factors.' This is a departure from the mindset that a perfect lifestyle negates genetic risk. Instead, he argues that even with optimal lifestyle, high Lp(a) still confers substantial risk, but optimizing everything else can bring the absolute risk down to an acceptable level. The key modifiable factors he singles out are LDL, blood pressure, blood sugar, and BMI—the familiar cardiovascular risk quartet. He does not give specific targets for each beyond LDL, but the message is clear: if Lp(a) is high, the aggressiveness of risk factor control should be proportionally higher across the board.

The study reinforces that Lp(a) is not a binary 'high/low' variable but a continuous risk driver. The subgroup analysis within the same paper demonstrated that people with the highest Lp(a) who aggressively lowered their LDL cholesterol ended up with a risk profile similar to the lowest-Lp(a) group not taking lipid-lowering drugs. This suggests that while we await specific Lp(a)-lowering therapies, aggressive LDL control can largely neutralize the excess risk. The practical implication is that measuring Lp(a) once can reclassify risk and motivate a much more intensive LDL target.

The speaker explains that because Lp(a) levels are genetically determined and largely unresponsive to lifestyle, the most powerful lever we have today is to 'starve the fire of fuel' by drastically reducing the number of LDL particles. The study’s subgroup analysis shows that individuals with the highest Lp(a) who also aggressively lowered LDL had outcomes comparable to the lowest Lp(a) group not on medication. This suggests that the absolute risk conferred by Lp(a) is heavily modulated by ambient LDL concentration, making LDL control the primary target. Statins can modestly increase Lp(a) levels, but their net benefit on LDL reduction still yields a significant overall risk reduction, so they remain first-line.

The speaker mentions that when he sees a patient with high Lp(a), he now considers aspirin. The rationale is that Lp(a) not only promotes atherosclerosis but may also increase thrombotic tendency, so aspirin’s antiplatelet effect could mitigate that component of risk. While no large randomized trial has exclusively studied aspirin in high Lp(a) for primary prevention, observational and subgroup data have suggested a net benefit. This is not yet a formal guideline but a clinician judgment based on emerging signals. The speaker presents it as a reasonable consideration alongside aggressive LDL lowering.